For decades, the framework for managing cardiovascular risk has focused on a familiar set of modifiable factors: cholesterol, blood pressure, blood sugar, and lifestyle choices such as diet and physical activity. Interventions, from statins to dietary counseling, are built upon this foundation. Yet, a significant component of an individual’s risk profile, one determined not by behavior but by genetics, has remained largely outside the reach of therapeutic intervention. This factor is Lipoprotein(a), or Lp(a), a causal and independent risk factor for atherosclerotic cardiovascular disease.
Millions of individuals worldwide carry elevated levels of Lp(a) due to their genetic inheritance, placing them at a higher baseline risk for heart attack and stroke, often irrespective of otherwise optimal health metrics. With no currently approved therapies specifically designed to lower it, elevated Lp(a) has represented a significant unmet need in preventive cardiology. This is the context for one of the most anticipated clinical trials in recent years: the Lp(a) HORIZON cardiovascular outcomes study, a large-scale investigation of the RNA-based medicine pelacarsen, sponsored by Novartis. The trial, which completed enrollment of over 8,000 participants in 2022, is poised to provide a definitive answer to a critical question: does lowering Lp(a) translate directly to a reduction in major cardiovascular events?
Understanding the Target: Lipoprotein(a)
To appreciate the significance of the HORIZON trial, one must first understand its target. Lipoprotein(a) is a complex plasma lipoprotein structurally similar to low-density lipoprotein (LDL), the so-called “bad cholesterol.” However, it has a crucial distinction: an additional protein called apolipoprotein(a), or apo(a), is attached to its surface. This unique structure confers properties that make it particularly pathogenic.
Lp(a) is considered to be atherogenic, prothrombotic, and pro-inflammatory. Its LDL-like component contributes to the buildup of atherosclerotic plaque in artery walls, the foundational process of most cardiovascular disease. Simultaneously, the apo(a) component is structurally similar to plasminogen, a key protein involved in dissolving blood clots. By competing with plasminogen, apo(a) is thought to impair the body’s natural clot-busting ability, thereby promoting thrombosis—a primary trigger for heart attacks and ischemic strokes.
Crucially, an individual’s Lp(a) level is overwhelmingly determined by genetics, with levels remaining relatively stable from early childhood throughout life. It is minimally influenced by diet, exercise, or body weight. Standard lipid-lowering therapies, including high-intensity statins, have little to no effect on Lp(a) concentrations. In some cases, statins may even slightly increase them. This genetic intransigence makes it a frustrating and challenging risk factor for both clinicians and patients. Approximately 20% of the global population, or more than one billion people, is estimated to have elevated Lp(a) levels (typically defined as >50 mg/dL or >125 nmol/L), placing a vast number of individuals in a higher risk category for which specific treatment is unavailable.
A Novel Mechanism: Antisense Oligonucleotide Therapy
Pelacarsen represents a targeted approach to this problem, leveraging a technology known as antisense oligonucleotide (ASO) therapy. It is not a traditional small-molecule drug. Instead, pelacarsen is a synthetic, modified strand of nucleic acid engineered to be a mirror image—or “antisense” version—of a specific segment of messenger RNA (mRNA).
The mechanism is precise. The liver is the primary site of apo(a) protein production. The genetic instructions for building this protein are transcribed from DNA into mRNA, which then travels to the cell’s protein-making machinery. Pelacarsen is designed to intercept this process. Once administered, it travels to the liver cells and binds specifically to the mRNA that codes for apo(a). This binding event tags the mRNA for degradation by a cellular enzyme called RNase H1. The result is that the genetic message is destroyed before it can be translated into the apo(a) protein. No protein, no Lp(a) particle formation.
This approach effectively “turns down the volume” on the gene responsible for Lp(a) production without altering the patient’s underlying DNA. Earlier Phase 2 clinical trials demonstrated the biochemical efficacy of this mechanism, showing that pelacarsen could produce substantial, dose-dependent reductions in Lp(a) levels—in many cases exceeding 80% from baseline. The critical step, however, is moving from demonstrating biochemical change to proving a tangible clinical benefit.
The Lp(a) HORIZON Trial Design and Primary Objective
The Lp(a) HORIZON study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Its design is robust, aimed at generating the high-quality evidence needed to change clinical practice.
- Patient Population: The trial enrolled over 8,000 patients who have already experienced a cardiovascular event, such as a heart attack or stroke. This is a secondary prevention population, meaning they are already at high risk for a subsequent event. All participants also have elevated Lp(a) levels at baseline.
- Intervention: Participants were randomized to receive either pelacarsen (administered via subcutaneous injection) or a matching placebo, in addition to standard-of-care therapy for cardiovascular disease, which typically includes statins.
- Primary Endpoint: The trial’s primary objective is to determine if treatment with pelacarsen reduces the risk of an expanded composite of major adverse cardiovascular events (MACE). This endpoint typically includes non-fatal myocardial infarction (heart attack), non-fatal ischemic stroke, and cardiovascular death. The fundamental goal is to prove that lowering Lp(a) with this specific agent prevents these hard clinical outcomes.
With results anticipated in early 2026, the study is one of the most closely watched events in cardiology. Its outcome will have profound implications for the field.
Potential Impact and the Future of Cardiovascular Risk Management
A positive result from the HORIZON trial would be a landmark achievement in cardiovascular medicine. It would validate the “Lp(a) hypothesis”—the long-held theory that elevated Lp(a) is not just a risk marker but a causal factor in disease progression. If pelacarsen is shown to be safe and effective, it would likely become the first approved therapy specifically for lowering Lp(a) to reduce cardiovascular risk. This would trigger a cascade of changes in clinical practice:
- Expanded Screening: Measurement of Lp(a) is not currently a routine part of standard lipid panels. A positive trial would almost certainly lead to updated clinical guidelines recommending broader, perhaps even universal, screening for Lp(a) at least once in an adult’s lifetime.
- A New Therapeutic Pillar: Clinicians would have a new tool to treat residual risk in patients who still experience cardiovascular events despite optimal management of LDL cholesterol and other risk factors.
- Refined Risk Stratification: Knowledge of a patient’s Lp(a) status would become a critical data point in assessing their overall lifetime risk for cardiovascular disease, allowing for more personalized and aggressive preventive strategies.
Conversely, a neutral or negative result would be a significant setback. It would force researchers to question whether Lp(a) is truly a modifiable target or if the health consequences of its elevation are established too early in life to be reversed by intervention in adulthood. (Frankly, this would be a deeply disappointing outcome for the field).
The landscape of Lp(a)-lowering therapies is also growing. While the Novartis/Ionis pelacarsen trial is the most advanced, other companies, including Sionna Therapeutics and others, are developing their own approaches, underscoring the intense industry interest in this target. The HORIZON trial, as the first to reach the finish line, will set the precedent.
In conclusion, the Lp(a) HORIZON study is more than a test of a single drug. It is a referendum on a fundamental aspect of cardiovascular risk that has been understood for decades but has remained untreatable. The data, when released, will provide a clear signal, shaping the direction of preventive cardiology and offering potential new hope for the one in five individuals worldwide living with this silent genetic risk.